Company & Sponsor Intelligence

Rovi Pharmaceuticals Laboratories

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed3

Countries1

Therapeutic footprint

schizophrenia

Indexed studies

NCT05179525Comparative Bioavailability of Risperidone.
schizophrenia · United StatesPHASE1

NCT03527186Comparative Bioavailability of Risperidone
schizophrenia · United StatesPHASE1

NCT03870880Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
schizophrenia · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →